Journal
DRUG RESISTANCE UPDATES
Volume 5, Issue 3-4, Pages 131-146Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/S1368-7646(02)00003-1
Keywords
xiap; PI3K/Akt; ovarian cancer; chemoresistance
Categories
Funding
- NCI NIH HHS [CA89242] Funding Source: Medline
Ask authors/readers for more resources
Although cisplatin derivatives are first-line chemotherapeutic agents for the treatment of epithelial ovarian cancer, chemoresistance remains a major hurdle to successful therapy and the molecular mechanisms involved are poorly understood. Apoptosis is the cellular underpinning of cisplatin-induced cell death, which is associated with expression of specific death genes and down-regulation of survival counterparts. The X-linked inhibitor of apoptosis proteins (Xiap), an intracellular anti-apoptotic protein, plays a key role in cell survival by modulating death signaling pathways and is a determinant of cisplatin resistance in ovarian cancer cells in vitro. This review focuses on the role of Xiap and its interactions with the phosphoinositide-3 kinase (PI3K)/Akt cell survival pathway in conferring resistance of ovarian cancer cells to chemotherapeutic agents and discusses potential therapeutic strategies in overcoming chemoresistant ovarian cancer. (C) 2002 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available